University of North Dakota

UND Scholarly Commons
Physician Assistant Scholarly Project Papers

Department of Physician Studies

5-2020

Treatment of Clostridioides Difficile with Fecal Microbiota
Transplantation
Brenton Green
University of North Dakota, brenton.green@und.edu

See accompanying poster for this paper at:
Follow this and additional works at: https://commons.und.edu/pas-grad-papers
Part of the Medicine and Health Sciences Commons

Recommended Citation
Green, Brenton, "Treatment of Clostridioides Difficile with Fecal Microbiota Transplantation" (2020).
Physician Assistant Scholarly Project Papers. 69.
https://commons.und.edu/pas-grad-papers/69

This Scholarly Project is brought to you for free and open access by the Department of Physician Studies at UND
Scholarly Commons. It has been accepted for inclusion in Physician Assistant Scholarly Project Papers by an
authorized administrator of UND Scholarly Commons. For more information, please contact
und.commons@library.und.edu.

Running Head: TREATMENT OF CLOSTRIDIOIDES DIFFICILE

Treatment of Clostridioides Difficile with Fecal Microbiota Transplantation
Brenton Green, PA-S
Bachelor of Science, North Dakota State University 2009
Contributing Authors: Jay Metzger, PA-C
Rebecca Andes M. Mgt, MSN, APRN, FNP-C

A Scholarly Project
Submitted to the Graduate Faculty of the University of North Dakota
in partial fulfillment of the requirements for the degree of
Master of Physician Assistant Studies
Grand Forks, North Dakota
May 2020

1

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

2

Table of Contents
Acknowledgements………………………………………………………………………………..3
Abstract…………………………………………………………………………………………....4
Introduction………………………………………………………………………………………..5
Literature Review………………………………………………………………………………….6
Epidemiology and Pathophysiology of Clostridioides Difficile…………………………..7
Treatment Considerations with Initial and Recurrent CDI………………………………13
Fecal Donor Guidelines and Screening Process…………………………………………17
Safety, Efficacy, and Indications for Fecal Microbiota Transplant……………………...21
Discussion………………………………………………………………………………………..31
Application to Clinical Practice………………………………………………………………….35
References………………………………………………………………………………………..37

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

3

Acknowledgements
I would like to thank my advisor Jay Metzger for his assistance with this project. Daryl Sieg was
readily available to answer questions, and provided excellent guidance to maximize efficiency.
Another important figure was Rebecca Andes for her guidance through the subject matter and
applicability to clinical practice in our region. Lastly, I would like to thank my family for their
endless support as I attain a Master’s degree in Physician Assistant Studies.

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

4

Abstract
Research was performed to discuss the epidemiology and current guidelines of Clostridioides
difficile infection (CDI), recurrent C. difficile infection (rCDI), the different modalities of fecal
microbiota transplantation (FMT), the donor screening process, as well as the safety and efficacy
of treatment. Utilizing Clinical Key, NCBI database, Dynamed Plus, Cochrane Review, and the
websites for the CDC and FDA, a literature review was produced, encompassing recent research
and human studies related to CDI. Recent studies were preferred, however since C. difficile has
sparsely changed, older data was utilized with updates applied accordingly. Articles excluded
were due to not meeting the themes within the literature review. Due to the ease of use, oral
antibiotics are the proven mainstay for initial infection with C. difficile; while FMT has been
shown to reduce recurrence after multiple infections. The study methods may vary; however,
similar results exist with efficacy and safety for FMT in regards to oral, fresh versus frozen stool,
or rectal administration of therapy. With proper screening, FMT is relatively safe and
efficacious. The need for long-term studies on the safety of FMT has been established and are
underway.
Keywords: Clostridium difficile, Clostridioides difficile, treatment, fecal donor screening,
fecal microbiota transplantation, FMT, safety, efficacy, recurrent C. difficile, guidelines for
screening and treatment, epidemiology, transmission of CDI, and comparison studies.
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Introduction
Clostridioides difficile infections (CDI) continue to rise, can be recurrent, and may be
challenging to treat. Infection may be hospital or community-acquired. It is essential to recognize
CDI early and facilitate treatment for better outcomes. Oral antibiotic regimens are intended for
initial disease and early recurrence; on the other hand, fecal microbiota transplant (FMT) therapy
should be considered with persistent cases of recurrence to reset the healthy microbial flora
within the gut. While the long-term safety data is limited in FMT treatment, it is considered
relatively safe and efficacious with proper screening techniques for donor and patient.
CDI costs on average 4.8 billion dollars per year. In 2011 the CDC estimated nearly
500,000 cases with 30,000 deaths. Different strains of C. difficile pertain to various geographical
regions (Guery et al., 2019). Ribotype 027 is a hypervirulent strain that has demonstrated
resistance to treatment in the United States (Song and Kim, 2019). Antibiotics, gastric acid
suppressants, and hospital service areas that are hot spots for CDI, increase the risk for infection
(Zacharioudakis et al., 2019).
The 5 Ds will assist in determining treatment options in regard to FMT (Allegretti et al.,
2019). The current guidelines for stool donation are more of a recommendation. Due to gaps in
knowledge, creating guidelines for fecal donor selection with FMT remains difficult. As more is
learned about FMT and the potential for harm, the guidelines will continue to evolve. Research is
currently underway for using FMT beyond CDI.
Metronidazole used to be the industry standard for initial treatment in C. difficile
infection. It is inexpensive, effective, and has a low adverse side effect profile. Guery et al.
(2019) performed a comparison of vancomycin and metronidazole, which demonstrated no
difference in mild disease, but vancomycin is superior to metronidazole in treating severe disease
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(97% vs. 76%; P=0.02). Vancomycin and fidaxomicin are both utilized in recurrent CDI;
however, they are inferior to FMT (Hvas et al., 2019). Due to the increased risk of adverse
events related to FMT, in contrast to, the decreased risk and cost for vancomycin treatment, the
question becomes at what point in recurrent disease is FMT utilized?
The FDA (2019) highlights an important cause for concern with FMT use as well as an
update to the 2013 guidelines. All the risks involved with transplanting fecal material in an
attempt to re-colonize the gut remains unknown and caution is advised. Patients should have an
understanding of the risks, benefits, and alternatives to treatment before consulting with
infectious disease providers. For providers in rural communities where referral may be hours
away, this requires more significant consideration. A barrier to using FMT may stem from the
lack of long-term safety studies or the public view on fecal transplant. The subject of C. difficile
is broad; the goal of this review is to apply current guidelines into clinical practice so the
provider and patient can make an informed decision together.
The literature review will address topics such as, when should FMT be considered in
therapy? What are the current guidelines and screening for proper stool donors? Is Oral FMT
more effective than rectal FMT in the treatment of recurrent CDI? Do the adverse effects of FMT
change based on the route of administration?
Literature Review
A review of the literature shows an influx of C. difficile infections as well as different
treatment options for CDI. The evolution of treatment is adapting with newer research and
controlled studies; however, an absence of knowledge still exists. Some challenges include
standardization of donor stool protocols, patient or provider perception of fecal transplantation,
and long-term studies evaluating safety and efficacy of FMT.
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Epidemiology and Pathophysiology of C. Difficile
Clostridioides difficile infection (CDI) was formerly known as Clostridium, and is the
leading cause of pseudomembranous colitis (Guery et al., 2019). CDI has been primarily
associated with antibiotic use, hospital acquisition, and defined by the symptomatology.
Upwards of 15 percent of healthy adults may be asymptomatic carriers of C. difficile. To be
asymptomatic means colonization of the organism is present but the symptoms are not. Clarkin
et al. (2019) note the change in 2017 to redefine initial disease as either non-severe, severe, or
fulminant. Non-severe is classified by a white blood cell (WBC) count less than 15000/microliter
and serum creatinine less than 1.5 mg/dL. Severe disease will have a WBC count greater than
15000/microliter or serum creatinine greater than 1.5 mg/dL.
Symptoms of CDI are related to gastrointestinal discomfort, nausea, vomiting, diarrhea,
pain, fever, and loss of appetite. Other concerns are dehydration, hypotension, and electrolyte
imbalance from a large amount of fluid loss, bowel perforation, renal failure, and sepsis.
Fulminant disease may present as hypotension, shock, ileus, or megacolon with a high mortality
rate from surgery. According to Allegretti et al. (2019), colectomy has a 30-50% mortality rate.
FMT may help two populations: those who are too unstable to have surgery, and those who are
candidates for surgery but mitigate the risk after successful fecal transplant. Mortality has
decreased in fulminant colitis from 43% to 12% with fewer surgeries being performed.
In general, short-term side effects with FMT are self-limited, last less than 48 hours, and
are not typically serious for the immunocompetent (Rao et al., 2016). Common symptoms
include gastrointestinal upset, such as nausea, diarrhea, constipation, bloating, or cramping, and
may be based on the route of administration. Death following FMT is rare and not usually in
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direct correlation to therapy itself. One example is a patient who died of aspiration pneumonia
while undergoing anesthesia.
In 2011, the Center for Disease Control and Prevention (CDC) estimated nearly 500,000
cases of CDI, with nearly 30,000 deaths within the first thirty days of diagnosis. Communityacquired infection occurs in 25% of cases and affects those not taking antibiotics, as well as
youth. CDI acquired within the healthcare setting costs on average $4.8 billion and increases
mortality and morbidity. In 2013 the CDC brought this resistant threat to the forefront to increase
awareness and emphasis on early detection and treatment of disease.
Clarkin et al. (2019) describe C. difficile as a gram-positive, anaerobic, spore forming,
toxin producing bacillus. Two toxins comprise C. difficile infection, TcdA and TcdB. The toxins
start by causing an inflammatory reaction that disrupts the healthy gut microbiome and creates a
pseudo-membrane. Transmission is via the fecal-oral route. Contaminated surfaces may harbor
spores for days because they are tough to eradicate. The vegetative form of C. difficile is related
to the toxins that accumulate in disease. Guery et al. (2019) theorizes that since not all
individuals infected with C. difficile are symptomatic, an immune response, amongst other
reasons, may be the cause for symptoms.
C. difficile ribotype (RT) may be region-specific. RT 176 is predominately in eastern
Europe, RT 244 in Australia and New Zealand, RT 018 in Italy, and RT 017 in Asia. Within the
United States, 133 different ribotypes have been identified. C. difficile has been associated with
pork, veal, and horse. RT 078 has been colonized in farmers and pigs, which suggests
transmission between humans and animals. It has also been located within vegetables and
seafood, which creates the possibility of food-borne illness.
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RT 027 (Clarkin et al., 2019) is associated with fulminant colitis in America and consists
of nine percent of hospital-acquired and eight percent of community-acquired infections. Aside
from the increased rate in production of toxins A and B, RT 027 is resistant to fluoroquinolone
antibiotics. Respiratory and urinary infections are often treated with fluoroquinolones and
treatment is typically met with resistance.
Recurrent infection with C. difficile is a concern for anyone diagnosed with CDI. Risk
factors directly involved with the rate of recurrence are PPI or antibiotic use, being
immunocompromised, age greater than 65 years, severe or prior CDI, chronic renal
insufficiency, length of hospital stay, lack of immune response to toxins A or B, or being
infected with strain 027, 078, or 244 (Song & Kim, 2019). Hypervirulent strain NAP1/BI/027
has been shown to have a higher recurrence rate (27.4%) when compared to non-hypervirulent
strains (16.6%) in a clinical trial involving 719 CDI patients (p=0.002).
Clostridioides difficile is the most common hospital-acquired infection currently
(Zacharioudakis et al., 2019). To be considered healthcare facility-onset CDI (HO-CDI),
diagnosis must be 48 hours after admission. Ways to decrease transmission include antimicrobial
stewardship for providers, contact precautions when entering patient rooms, decontamination of
objects or surfaces with cleaning agents that specifically target C. difficile spores, hand-hygiene
with soap and water, and isolation of asymptomatic carriers within the hospital. Vicinity relative
to long-term care facilities (LTCF), use of gastric acid suppressants, or antibiotics are associated
with community-acquired CDI (CA-CDI) risk.
C. difficile infection that reoccurs within eight weeks of the initial infection is considered
recurrent CDI (Song & Kim, 2019). The initial recurrence rate is about 30 percent, the second
recurrence is 40 percent and a third recurrence is upwards of 65 percent. Recurrent CDI may be
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reinfection from the same strain or infection from a new strain. Increasing age is the most
reported risk factor related to recurrent disease. A retrospective study demonstrated recurrence
risk for individuals less than 17 years old (25%), 18-64 (27.1%), and those 65 and older (58.4%).
Being 65 years or older has an independent risk factor for recurrent CDI (RR 1.63; 95% CI, 1.242.14; P=0.0005). Antibiotic use is the most significant modifiable risk factor for recurrent CDI
(RR 1.76, 95% CI, 1.52-2.05; p<0.00001). Gastric acid suppressants are widely used, and in a
study of 7703 CDI patients, 22.1% had gastric suppression versus 17.3% that did not (OR 1.52,
95% CI, 1.2-1.94; p< 0.001).
Zacharioudakis et al. (2019) evaluated the most common antibiotics used from Medicare
claims, which consisted of fluoroquinolones (9,380,303), macrolides (6,150,460), penicillin
(4,403,630), 1st generation cephalosporins (3,161,724), sulfonamides (3,115,615), penicillin
combinations (1,926,431), clindamycin (841,056), and 2nd generation cephalosporins (660,197).
The acid suppressants consist of proton-pump inhibitors (PPIs) and histamine-2 receptor
antagonists (H2RA). PPI’s were widely utilized at 45,434,116 claims, while H2RA were utilized
8,732,397 times. These medications alter the normal gut microbiome and increase the risk of C.
difficile overgrowth.
Hospital service areas (HSA) were defined as hot spots with high rates of HO-CDI in
their region and surrounding community. Significant hot spots were mostly in the northeast,
consisting of Connecticut, Delaware, Massachusetts, New Hampshire, New Jersey, New York,
Pennsylvania, Rhode Island, Virginia, and West Virginia. Other regions included Michigan,
Ohio, California and Florida (z-score >1.95, p<0.05). The hot spots were further defined into
Combined Statistical Areas (CSA) that consist of Boston-Worcester-Providence, New YorkNewark, Philadelphia-Reading-Camden, Los Angeles-Long Beach, Detroit-Warrant-Ann Arbor,
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and Central-South Florida. The results of the study show that by decreasing the amount of
antibiotics prescribed by 10%, the rate of HO-CDI decreases by 5-23 percent. Reduction rates
are as follows: New England (23.1%), New York (13.7%), Detroit (10%), Florida (8.8%), Los
Angeles (8.3%), and Philadelphia (5.4%).
Khan et al. (2014) performed a study limited by a small test group and retrospective
nature. Nine patients were considered community-acquired and eleven had hospital-acquired
CDI. FMT was delivered via colonoscopy, and resolution of symptoms within three months was
considered cured. A secondary cure required two treatments with FMT. Treatment failure was
defined as more than three loose or watery stools per day and a positive PCR for C. difficile. The
average age was 64 (+/- 10.26) years for community-acquired, while hospital-acquired was 68.27
(+/- 17.88) years (p=0.361). Infection prior to CDI diagnosis for three patients involved either
cellulitis or urinary tract infection, two had dental infections, and one did not have any infection
for the community-acquired group. Within the hospital-acquired group, four had pneumonia, five
had urinary tract infections, and one had either osteomyelitis or sepsis. Prior to CDI diagnosis,
fluroquinolones were used in 55% of inpatient treatment, whereas 33% and 44% of outpatients
were prescribed clindamycin and beta-lactam antibiotics, respectively.
The average resolution of symptoms was 4.5 days and 4.45 days for community and
hospital-acquired CDI, respectively (p=0.328). In the six months that followed FMT, no patients
required another treatment in the community-acquired group. Thus, the primary cure rate was
100 percent. The hospital acquired group had 82% (9/11) primary cure rate with 100% secondary
cure rate. Of the two that required a second course of FMT, one had toxic megacolon that was
relieved within seven days of the first treatment; the second patient had a history of colitis with
recurrent CDI after taking Augmentin for a dental procedure. The second FMT was performed
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78 days after the initial procedure, and the secondary resolution of symptoms occurred two days
later. Neither case had a recurrence of symptoms at follow-up six months later.
The community-acquired group consisted of 88.9% females (8/9) and the hospitalacquired group had 45.5% females (5/11). Young children are carriers of C. difficile and require
frequent diaper changes increasing exposure to fecal material. It has been proposed that females
may acquire CDI within the community at higher rates due to their increased role as caregivers.
In comparing recurrence, community-acquired (44/128; 34.4%) was more common than
hospital-acquired (19/87; 21.8%) CDI (P=0.047). Unsurprisingly, hospital-acquired infection
was more commonly involved with recent antibiotics (61% vs. 41%; P=0.004) and
immunosuppressed patients (60.5% vs. 19%; P<0.001). No statistical significance was related to
age (P=0.201), sex (P=0.184), or irritable bowel disease (P=0.061). Aldrich et al. (2019)
compared his study to recent literature, and found a higher recurrence rate (29% vs <20%);
which may be related to treatment decision, since this was performed during the old guidelines
where metronidazole was a first-line agent, and disease severity was not classified.
Inclusion criteria consisted of 175 patients with 215 treatment encounters, however data
was only available for 207 encounters. Recurrence occurred in 29% (63/215) of all treatments,
with 29% (42/145) being metronidazole, 36.5% (11/30) vancomycin, and 39% (9/23)
combination therapy (P=0.356). Ten patients had FMT, of which eight were successful on the
first treatment. The remaining two were successful after an additional treatment (10/12; 83%).
Colonoscopy was performed on seven of the eight who had success with one treatment, while the
two failures were related to nasojejunal or gastric tube.
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Treatment Considerations with Initial and Recurrent CDI
Agrawal et al. (2016) studied the safety and efficacy of FMT within the high-risk
population of those 65-97 years-old. Accordingly, 92% of deaths related to C. difficile occur in
the elderly. The study utilized the evaluation of recurrent, severe, and complicated CDI with
long-term follow up. Treatment with vancomycin, fidaxomicin, or metronidazole is less likely to
benefit the elderly population. It is unknown whether the elderly population has increased risk of
FMT complications with their decreased immune response and co-morbidities, which
necessitates the long-term evaluation of safety in those greater than 65 years of age.
The majority of FMT in this study was via colonoscopy (80.8%) with EGD (9%), push
enteroscopy (2%), flexible sigmoidoscopy (6.2%), and fecal enema (2%) as alternative methods.
Preparation of donor stool depended on installation, but typically 60-100 grams of stool were
mixed with saline. For EGD or push enteroscopy, 75-200mL was infused into the duodenum or
jejunum. With colonoscopy, 250-400mL was initiated into the cecum, proximal, or distal colon.
Infusion of 150-200mL was used for retention enema, and the patient was required to retain the
donor stool for 2-6 hours for maximum benefit.
The study started with 168 eligible patients, but after excluding 22 patients, 146
participated in the study. The majority were women (68.5%) with an average age of 78.6. The
typical follow-up period was 12.3 months, but ranged from 1-48 months. Recurrent CDI was the
most commonly treated group at 89 (61%). Severe and complicated CDI were treated in 45
(30.8%) and 12 (8.2%) patients, respectively. The primary cure rate was highest in severe CDI at
91%, followed by recurrent CDI at 82%, and lastly 66% with complicated infection. Overall, the
primary cure rate was 121 out of 146 (82.9%).
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Recurrence of disease occurred in 25 patients within the 12-week allotment period
following FMT. Causes varied from antibiotic use for other infections (10/25; 40%), admission
to the hospital or returning home to a long-term care facility (5/25; 20%), and having surgery
(1/25; 4%). Symptoms mainly consisted of diarrhea or abdominal pain. The secondary cure rate
was seen in 140 out of 146 patients (95.9%). Of the twenty-five patients, seven (28%) were able
to see resolution with antibiotics alone, while twelve (48%) had a course of antibiotics and FMT.
When the data was collected for this study, four of the six patients who did not achieve
resolution were receiving vancomycin therapy, and two were on the waitlist for FMT. One of the
patients was on prophylactic antibiotics due to a prosthetic heart valve, which may have
contributed to recurrence.
The therapeutic response to FMT was overwhelmingly positive in regards to the
elimination of diarrhea (126/146; 86.3%). For those that documented specific response times to
achieve improvement or resolution of symptoms, almost half had resolution in one day (53/110;
48.2%), with the remainder over two days (15/110; 13.6%), one week (26/110; 23.6%), one
month (13/110; 11.8%), or three months (3/110; 2.7%).
No direct complications were reported from FMT. Minor adverse side effects were noninfectious diarrhea in seven (4.8%) and constipation in four (2.7%) patients. Serious adverse
events were calculated for the full 12-week follow-up period and consisted of six hospitalizations
for recurrent diarrhea. One patient had an initial resolution of symptoms with FMT; however, the
infection recurred four days after returning to her long-term care facility (LTCF) and was
complicated by an ileus. The patient passed away two weeks later. Another case of recurrent CDI
was complicated by cytomegalovirus (CMV) colitis. The patient had an initial response to FMT
but died one year later due to perforation of the colon. Deaths that were unrelated to FMT
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included: heart failure (4), cancer (3), stroke, pneumonia, and Alzheimer’s disease (1 each). The
remaining patients had resolution of symptoms with FMT and/or vancomycin treatment without
complications.
Metronidazole used to be the first-line oral agent in the treatment of initial C. difficile
infection, but due to high failure rates and recurrence, it has been replaced by vancomycin
(Clarkin et al., 2019). The only caveat is if vancomycin or fidaxomicin is unavailable due to cost
or access, then metronidazole may be used. The superiority of vancomycin has been proven in
both mild and severe CDI. It is common with vancomycin or fidaxomicin to have resolution
within 10-14 days of therapy. Cost continues to be a barrier in using fidaxomicin. Seizure,
peripheral neuropathy, nausea, and a metallic taste in the mouth are adverse side effects of
metronidazole use. If combined with alcohol a disulfiram-like reaction occurs where the
individual may feel flush, nauseous, crampy, vomit, or acquire a headache.
Oral vancomycin is not absorbed during ingestion, so it is only used to treat CDI. Due to
the lack of systemic absorption, vancomycin is typically well-tolerated; however, nausea,
abdominal pain, and hypokalemia may occur. Vancomycin has become more accessible with its
reduction in cost. Fidaxomicin is similar to vancomycin with its minimal absorption and
tolerability. The recurrence rate of CDI is less with fidaxomicin compared to vancomycin. Side
effects from treatment include abdominal pain, nausea, vomiting, hemorrhage (GI), anemia,
neutropenia, angioedema, dyspnea, pruritis, and rash.
Rifaximin may be used off label for recurrent episodes of CDI as an adjunct therapy.
Unfortunately, cost remains high and extended use may promote opportunistic infection. Side
effects seen include peripheral edema, headaches, dizziness, fatigue, ascites, and increased liver
function studies, specifically, serum alanine aminotransferase.
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Bezlotoxumab is used as an adjunct to therapy in recurrent CDI and has been proven
effective at any point during antibiotic therapy. It works by acting against toxin B. Treatment is
administered over an hour via an intravenous catheter. Administration reactions are minimal but
may include pyrexia, headache, and nausea.
Treatment options depend upon the severity of disease. Non-severe disease recommends
Vancomycin 125mg four times daily for ten days, or Fidaxomicin 200mg twice daily for ten
days. If neither of these first-line agents are available, Metronidazole 500mg may be used three
times daily for ten days. With severe disease the same dose and timing of Vancomycin or
Fidaxomicin are utilized, however, Metronidazole is not recommended. Fulminant disease
requires Vancomycin 500mg four times daily in addition to Metronidazole 500mg intravenously
every eight hours. If an ileus is present with fulminant disease, another treatment option would
be to mix 500mg of Vancomycin into 100-500mL of normal saline and perform a retention
enema over 30-60 minutes.
It is estimated that nearly 30% of initial treatment fails to completely clear the infection,
leading to the recurrence of disease. The treatment course will depend upon what medication was
used in the initial encounter. If Metronidazole was used, then the recommendation is for a tenday course of vancomycin, whereas if vancomycin was used initially, then either a ten-day
course of fidaxomicin or a prolonged and tapered vancomycin regimen is used. Vancomycin
taper consists of 10-14 days of 125mg four times daily, then twice daily for a week, then once
daily for a week, followed by 2-8 weeks of every second or third-day dosing. Treatment options
for multiple recurrences include prolonged and tapered vancomycin, or a ten-day course of
vancomycin followed by rifaximin 400mg three times daily for twenty days, or fidaxomicin for
ten days, or fecal microbiota transplant.
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Guery et al. (2019) performed a comparison of vancomycin and metronidazole as a
randomized, double-blind study with 172 participants who were followed for 21 days. Disease
severity was used to differentiate the group. The overall cure rate, which was determined by the
lack of infection at day 21, was 97% in the vancomycin group and 84% in the metronidazole
group (P=0.006). No difference was noted in mild disease; however, for severe disease,
vancomycin was superior at 97% as compared to metronidazole at 76% (P=0.02).
In a comparison study, pulsed fidaxomicin was proven superior to a standard 10-day
course of vancomycin. Pulsed fidaxomicin is using 200mg twice daily for five days, followed by
once-daily dosing every other day for eighteen days. Clinical cure was determined to be 30 days
beyond the last day of treatment. Pulsed fidaxomicin had a cure rate of 70 percent, while
standard vancomycin cured 59 percent.
Fecal Donor Guidelines and Screening Process
Donor screening for a retrospective study at the University of Toledo Medical Center
between July 2012 and August 2013 involved both stool and serum testing (Khan et al., 2014).
Stool testing consisted of CDI toxin PCR, bacterial culture for enteric pathogens, ova and
parasites, cryptosporidium antigen, and microspora. Serum testing included hepatitis A, B, C,
antibodies for HIV 1, 2, human T lymphotropic virus, and Helicobacter pylori. Plasma testing
for the syphilis enzyme was also performed. Potential donors did not have antibiotics three
months prior to donation and lacked gastrointestinal symptoms.
Stool transplant is viewed similarly to organ transplantation and the screening process
must reflect these standards (Vyas et al., 2015). The difficulty with creating guidelines lies in the
relative infancy of FMT and lack of long-term data. As more is learned about proper screening
techniques, sophisticated guidelines will dictate the process. Currently, hepatitis A, B, and C,
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syphilis, human immunodeficiency virus (HIV), and stool culture for pathogens are screened at a
minimum. The medical history should include travel to areas endemic to diarrhea, high-risk
sexual activity, infectious and autoimmune disease, cancer, and inflammatory bowel disease.
Barriers to FMT include the unflattering nature of treatment, risk for transmission of
disease, lack of standardization, slow nature of the screening process, and laboratory costs. The
risk of the donor acquiring a pathogen between screening and the procedure exists. One way to
mitigate this risk includes using the donor stool for analysis, and freezing it for future use upon
favorable testing results. The Investigational New Drug (IND) policy may be seen as a barrier for
providers or patients; however, it is beneficial due to the data collected. As regulations continue
to surface, patient safety and access to care should not be put in jeopardy.
Fecal material is not being classified as a drug, but it could be manufactured as one.
Manufacturers of stool donation specimens could provide a controlled environment for a
consistent and regulated product. Potentially, this could reduce cost, increase access to FMT
through frozen stool, and provide standardization in fecal donor screening protocols. The FDA is
currently conducting phase one and two trials in regard to fecal samples, and until
standardization occurs, they recommend submitting for an IND to increase statistics from the
public sector undergoing fecal transplantation.
Fecal microbiota transplantation has been shown to alter the gut of an individual
colonized with C. difficile to mimic that of a healthy individual within one day after therapy and
last for up to one year (Allegretti et al., 2019). There is an abundance of clinical trials currently
investigating FMT use, such as for sclerosing cholangitis, type 2 diabetes mellitus, irritable and
inflammatory bowel disease, and other causes of multi-drug resistant organisms (Woodworth at
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al., 2017). As new information is released it could alter the course of management for multiple
diseases.
In 2013, the FDA expressed their concern over stool being a biologic agent and their
intent to classify stool as a medication in the treatment of disease. The FDA, in combination with
other professional societies, drafted some guidelines to fecal donor selection. The current
recommendation is to use donors who are familiar with the provider or the patient for the
benefits. Interestingly enough, most clinical trials are sourced from stool banks and unknown
donors. Depending upon the regulations, stool banks may be required to apply for IND to remain
in compliance, or the healthcare facility may be required to develop their own regulations for
screening and donor selection. The discussion has suggested that fecal material could be
considered more tissue-based and regulated in a similar fashion to blood banking.
Fecal donor selection consists of a screening questionnaire to identify risk within the past
medical history to reduce disease transmission. Diagnostic studies are performed and analyzed
prior to therapy. The FDA continues to monitor screening methods and donor selection in an
attempt to maximize safety.
Screening asymptomatic donors may provide increased false-positive rates, as well as
decreased sensitivity with testing because these tests have not been validated. Blastocystis has
been found in 32.5% of healthy individuals relating to a diverse gut microbiome and possibly a
factor in irritable bowel syndrome; research is on-going to establish the link between protozoa
and the healthy gut microbiome. Similarly, to screen the feces for potential pathogens has not
been validated by polymerase chain reaction (PCR) despite the recognition of its importance.
Asymptomatic carriers of C. difficile are essential to identify prior to FMT. A study in
Japan used PCR to identify 7.6% of healthy adults as carriers, while 4.8% were carriers in
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Canada. It is still unclear the best screening method for the asymptomatic C. difficile carrier
since most laboratory testing is validated for loose or watery stools, not regular stools. PCR is
considered 90% sensitive and 95% specific when compared with the culture of loose, watery
stool. Future studies are needing to validate PCR with formed stools of asymptomatic
individuals. Microscopic examination for ova and parasites, antigen testing, and culture are
commonly performed on donor stool.
Multidrug-resistant organisms (MDRO) may make treatment difficult for certain
infections due to gut colonization. Using FMT will reset the normal gut microbiome and
decrease the amount of MDRO within the gut. Screening genome sequences for resistance would
be costly and isn’t recommended for everyone at this time. Carbapenem and vancomycinresistant Enterobacteriaceae may be beneficial to screen prior to FMT and utilized as exclusion
criteria for donation. Screening is limited for viruses, fungi, and parasites, requiring more time to
develop.
Obese patients above a body mass index (BMI) of 30 are typically excluded during
screening. A case occurred where a patient became obese after FMT from a known donor. Other
metabolic disorders and malnutrition are also criteria of exclusion; however, insulin sensitivity
has been shown to improve, which may lead to further research in the future.
Conditions that may impact the normal microbiome include C. difficile infection,
colorectal cancer, inflammatory bowel disease, cardiovascular disease, and colonization of
MDRO. Environmental influences include antibiotics, breastfeeding and early development for
children, diet and animal proteins, healthcare exposure, and international travel. Studies are
currently trying to identify colorectal cancer influences. Fusobacterium spp and Fusobacterium
nucleatum have both been implicated in this development. Currently, there is not enough
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information to regulate oncogenic screening protocols implicating the screening process. Some
argue that it is better to use donors that are less than 50 years of age where the risk of colorectal
cancer is theoretically less, but unknown. In contrast, others maintain that if the donor is older
than 50 with appropriate screening, the risk may be less than the younger donor. As more is
known about oncogenic screening and the gut microbiome, screening protocols will become
more apparent.
Safety, Efficacy, and Indications for Fecal Microbiota Transplant
According to the FDA (2019), during investigational FMT, two immunocompromised
patients acquired multi-drug resistant organisms (MDRO) from donor stool. The FDA has
provided an alert regarding the investigational use of FMT in treatment and its potential to cause
harm. Risks should be discussed with patients, or those with decision-making capabilities, prior
to treatment. Care must be exercised when screening for stool due to one patient death after
colonization of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (E. coli).
Another patient who was infected from the same donor stool survived. Both patients and the
donor stool tested positive for ESBL. The FDA reminds providers about the possibility of
transmitting MDROs with fecal transplantation and has issued the following changes: donor
screening must address risk factors for MDRO via questionnaire and testing of stool with the
exclusion of high-risk donors and/or MDRO positive colonization. The FDA would also like
providers to report any adverse events related to FMT to their MedWatch program.
The perception of FMT is often unsightly (Rao et al., 2019). In a survey of 192 patients,
81% would agree to have FMT performed for a hypothetical C. difficile infection. The main
reason for the remainder of negative responses was due to the thought of stool collection and
using a nasogastric tube for administration. Results were slightly more positive at 90% if they
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were able to use a pill (P=0.002). The same group then interviewed 135 physicians for their
perceptions of FMT. The results demonstrated that 65% (83/135) did not offer FMT to their
patient due to barriers from the institution, assumption the patient would not be interested in the
treatment, or apprehension with indications for therapy. The belief was that only 8% would
accept FMT if offered. The large gap between the providers belief and what the patient would
hypothetically approve for treatment, demonstrates a treatment bias. In order for FMT to thrive
as a treatment option in recurrent CDI, providers must be aware of their misconceptions and
remain unbiased when offering treatments.
Long-term studies are lacking due to the recent popularity of FMT treatment. Knowledge
of the mechanism between the host and the gut microbiome is not entirely understood at this
time, and more long-term data is needed to evaluate safety and efficacy. One study followed 77
patients for 3-68 months, with an average of 17 months, and new medical conditions surfaced. It
is difficult to ascertain if FMT may have caused stroke, myocardial infarction, cancer or
autoimmune disease, because the data in unavailable to correlate. Moving forward, researchers
should track FMT populations to determine cause and effect.
There are 5 Ds for the use of FMT. The first is decision making. Those with recurrent
CDI are eligible, but it is not recommended for the initial disease at this time. The second is
donor. Depending upon the facilities protocol, stool could come from a known donor or a bank.
The stool should be screened to reduce adverse events. Third, a discussion should occur between
the provider and the patient about the risks, benefits, and alternatives to treatment. Delivery is the
fourth, and it will depend upon the institution at which it is facilitated. Some different modes of
delivery include colonoscopy, retention enema, oral capsule, upper endoscopy, nasogastric, or
nasojejunal tube. Lastly, discharge is performed following FMT and the patient should be
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educated on proper risk reduction methods for future colonization, as well as antibiotic
stewardship. Follow up should occur around eight weeks, unless reinfection occurs before this
time.
Long-term follow up remains limited, however, it has been recognized by the National
Institutes of Health-funded patient registry, and about 4000 patients are being followed over a
10-year period (NCT03325855). A 3-year study has found FMT to be safe and efficacious for C.
difficile throughout its follow up.
A German retrospective study consisted of 33 facilities and 133 patients. According to
Hagel et al. (2016) it is difficult to perform any randomized controlled trials due to the Germans
Medicine Act (GMA), but the author felt this was a good starting point for initializing further
studies. Under this act, FMT is seen as a treatment of last resort.
The average age was 75 years-old and the majority were female (64.7%). Co-morbidities
included cardiovascular (59.4%), gastrointestinal (32.3%), endocrinological (30.1%),
nephrological (25.6%), pulmonary (19.5%), psychiatric (15%), neurological (8.4%), urological
(3%), rheumatological (3%), orthopedic and oncological (2.3%), dermatological, and
ophthalmological (0.8%), and lastly patients without any co-morbid conditions (13.3%). Three
patients were taking chemotherapy (2.3%) and nineteen had other forms of immunosuppressive
medication (14.3%).
Pre-treatment of CDI was most commonly performed with metronidazole plus
vancomycin (61; 45.9%) or metronidazole plus vancomycin plus fidaxomicin (34; 25.6%).
Antibiotic induction prior to FMT was used in 99 patients (74.4%) with vancomycin alone being
utilized by 71 patients (53.4%); no induction was used for 28 patients (21.1%). Preparation for
FMT also consisted of bowel lavage in 117 patients (88%). Frozen donor stool was utilized in 20
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people (15%). The applications used consisted of colonoscopy (55; 41.4%), duodenal/jejunal via
direct endoscopy or tube (59; 44.4%), gastric via endoscope (4; 3%), capsule (13; 9.8%) or a
combination of both jejunal and colonic endoscopy (2; 1.5%).
Adverse side effects were rare, consisting of 16 encounters (12%). Most frequently seen
was nausea (5; 3.8%), fever or abdominal pain (3; 2.3%), belching, emesis, food intolerance or
throat/retrosternal discomfort (2; 1.5%), irritable bowel syndrome, polyneuropathy, or weight
gain of 10kg over a 1-year period after FMT (1; 0.8%). Related to the endoscopy procedure
itself, aspiration pneumonia, hemorrhage, and loss of a tooth occurred in one patient (0.8%) for
each event. Seven patients died during observational follow up (5.3%); six due to a solid tumor,
malignancy, UTI, pulmonary embolism, and pneumonia (2). One patient had a recurrence of CDI
within seven days after FMT; however, the official cause of death was listed as cerebrovascular
accident.
In regards to initial response to treatment, 124/132 (93.2%) responded positively on
average within one day after FMT treatment. The median follow-up was 141 days, with the
maximum being 1825 days. Achieving primary cure by 30 and 90 days was seen in 101/120
(84.2%) and 72/92 (78.3%) patients, respectively. Two FMTs were administered to eighteen
(13.5%) patients, and one (0.8%) required four treatments. Secondary response by day 30 and 90
was realized in 105/120 (87.5%) and 79/92 (85.9%) patients, respectively.
The primary response per route of administration was most successful with gastric (2/2;
100%) or combination (2/2; 100%) for both 30 and 90 days. With the small number of patients,
this may have impacted the high success rate. Colonoscopy was the second highest at 30 days
(43/48; 89.6%) and 90 days (25/30; 83.3%). FMT via capsule was a smaller population and
showed 84.6% (11/13) and 83.3% (10/12) resolution. Lastly, duodenal/jejunal was the least
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effective at 78.9% (45/57) and 74% (37/50). The response rate was not swayed by antibiotic
induction (84.2% yes, versus 84% no) or bowel lavage (83.8% yes, versus 86.7% no).
A single-center randomized control trial was performed by Hvas et al. (2019) for the
evaluation of FMT, vancomycin, and fidaxomicin in the treatment of recurrent C. difficile
infection. Standard therapy with fidaxomicin 200mg twice daily (24 patients), vancomycin
125mg four times daily for 4-10 days (24 patients) or ten days (16 patients), was performed prior
to FMT. Administration was via colonoscopy (19; 79%) or nasojejunal tube (5; 21%). Rescue
FMT was offered to patients who were too ill to be randomized or those who failed initial
treatment. There were 56 patients that failed the screening and 31 (55%, 95% CI) of them were
hospitalized (p<0.0001). At inclusion, 6 of the 64 (11%, 95% CI) patients were hospitalized.
Primary outcome was achieved with both clinical resolution and negative PCR for C.
difficile at 8 weeks without further need for treatment in 71% (17/24; 95% CI 49-87) with FMT,
33% (8/24; 95% CI 16-55) with fidaxomicin, and 19% (3/16; 95% CI 5-46) with vancomycin.
Hvas et al. (2019) compared FMT to fidaxomicin (P=0.009), FMT to vancomycin (P=0.001),
and fidaxomicin to vancomycin (P=0.31). The secondary endpoint was reached with clinical
resolution in 92% (22/24; 95% CI 73-99) of those who received FMT, 42% (10/24; 95% CI 2263) with fidaxomicin, and 19% (3/16; 95% CI 4-46) with vancomycin.
Within eight weeks of initial treatment, 24 of the 64 (37.5%) randomized patients had a
positive C. difficile test. All patients were given rescue FMT and 83% (20/24; 95% CI 63-95)
had clinical resolution with a negative CDI test at eight weeks. Of these patients, 50% (1/2; 95%
CI 1-99) were initially randomized to FMT, 82% (9/11; 95% CI 48-97) fidaxomicin, and 91%
(10/11; 95% CI 59-100) vancomycin. There were 56 patients that failed the initial screening for
various reasons. Standard vancomycin treatment followed by FMT was performed in 88%
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(49/56) and by eight weeks 80% (39/49; 95% CI 66-90) were negative for CDI with resolution of
clinical symptoms. These results were similar to those of the randomly controlled trial (P=0.43).
Adverse side effects were defined as occurring within 24 hours of FMT. Fourteen out of
twenty-four (58%, 95% CI 37-78) did not report any adverse side effects. Ten of the remaining
twenty-four (42%; 95% CI 22-63) reported diarrhea (3), abdominal pain (1), bloating (5), or
constipation (1). One serious adverse side effect may be linked to FMT. Three hours after the
procedure the patient was in her home when she had symptoms of sepsis, vomiting, diarrhea,
convulsions, and fever. She was not hospitalized and reported resolution of symptoms within 24
hours. Of the 64 patients, 29 (45%) reported adverse events without a fatality.
In a randomized clinical trial (RCT) fresh fecal material was compared to frozen (frozenand-thawed) stool to determine the efficacy of FMT in recurrent CDI. Lee et al. (2016) estimated
that up to 50% of recurrent infections are new infections due to dysbiosis. The role of FMT is to
reset the normal gut flora to reduce the chances of reinfection and/or recurrence. This study used
retention enema for convenience to the patient, instead of oral or colonoscopy. Frozen stool has
multiple benefits over fresh stool, such as, less donor screening, reduced cost, availability to
facilities that would otherwise be unable to complete the process due to a lack of resources, and
the immediate use of donor stool upon thawing.
Recurrent C. difficile infection is defined as symptoms for 48 hours or greater after ten
days of treatment and within the initial two months of infection. Refractory CDI is considered a
continuation or worsening of diarrhea plus fever greater than 38 degrees Celsius, abdominal
pain, or peripheral white blood cell (WBC) count greater than 15 x 10^9/L after 5 days of
vancomycin treatment of 500mg 4 times daily. Single recurrence CDI, neutropenia, WBC counts
greater than 30 x 10^9/L, or toxic megacolon patients were excluded from the study.
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With refractory C. difficile infection, all patients receiving antibiotic treatment were
discontinued 1-2 days prior to FMT. Fifty milliliters of fresh or frozen stool was used, and if
there was not improvement in symptoms by day four, the procedure was repeated. If the patient
did not respond to two rounds of FMT they could have another FMT or antibiotics. Fresh stool
was collected and used within 24 hours. Frozen stool was not stored for more than 30 days at -20
degrees Celsius, and thawed at 25 degrees Celsius overnight.
The study consisted of 232 patients, with 118 receiving fresh FMT and 114 receiving
frozen FMT. The groups were further divided into a per-protocol and modified intention-to-treat
(mITT). Primary resolution in the mITT group consisted of 75% (81/108) frozen as compared to
70.3% (78/111) for fresh FMT (difference 4.7, 95% CI, P< 0.001). In the per-protocol group,
frozen FMT was slightly inferior at 83.5% (75/91) versus 85.1% (74/87) for fresh FMT
(difference -1.6, CI 95%, P= 0.01). The study defined the non-inferiority margin to be -15% after
the literature review found fresh FMT to be 85% effective in the treatment of recurrent CDI. The
reason for decreased response in the mITT population is due to treatment failure with the use of
antibiotics between FMT, or the patients lost to follow up were reallocated to this group. Six
patients decided to go back on oral vancomycin after multiple failed attempts with FMT and
remained symptom free between 12-18-month follow-up. Four of these six had refractory CDI
prior to FMT, which may suggest the benefit of FMT.
The majority of adverse events from FMT was mild to moderate. Diarrhea was the most
common complaint (70%), flatulence (25%), constipation (20%), abdominal cramps (10%),
and/or nausea (5%). Other episodes reported, but listed as unlikely to be related to FMT,
consisted of urinary tract infection (UTI), respiratory tract infection (RTI), and blood in the stool.
Of the serious side effects, 12 (eight frozen, four fresh) required hospitalization after resolution
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of CDI that was unrelated to FMT. There was a total of 23 deaths in the study, 19 (six frozen,
thirteen fresh) were unrelated to FMT, and four (two frozen, two fresh) had unresolved CDI.
While there was a lower proportion of clinical response as compared to other studies, it
could be due to the larger number of participants, the ineffectiveness of retention enemas, or the
burden of morbidity in the study (Lee et al., 2016). Half (111/218; 51%) were inpatients during
the study, 66% (145/219) had moderate to severe CDI, and 42% (29/69) had the hypervirulent
ribosome strain 027. Of the patients with immunosuppression and irritable bowel syndrome, 93%
(27/29) and 83% (5/6), respectively, had resolution of recurrent CDI within two FMT treatments.
CDI-attributable mortality rate was between 5.7-6.9 percent. Another limitation to this study is
due to the 13-week follow-up, however, the author recognized the lack of long-term data and is
performing an extended 10-year follow up with these study participants.
Fecal microbiota transplantation may be performed via multiple routes. Rao et al. (2016)
performed a comprehensive review of 317 patients, 23% (73/317) had oral infusion, 35%
(111/317) had retention enema, and 42% (113/317) had infusion via colonoscopy in the
treatment of recurrent CDI. There were many differences with donors, infusions, and type of
administration; however, the efficacy demonstrated 89% had resolution of symptoms after one
treatment. A limiting factor for direct comparison of efficacy exists with the variance in data
collection and route of administration across studies.
Shogbesan et al. (2018) performed a systematic review of 44 studies and 303 patients to
evaluate the safety and efficacy of FMT within the immunocompromised population. The
majority of patients were on suppressant medication (77%), followed by solid organ
transplantation (18%), lymphoma or leukemia (16%), stem cell transplant (2.5%) and human
immunodeficiency virus or acquired immunodeficiency syndrome (2.1%) with almost 20%
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having more than one reason for immune suppression. The average patient had 2.5 episodes of C.
difficile infection prior to FMT. The majority of patients had antibiotic therapy prior to FMT.
Colonoscopy was administered in 76% of patients, with 21% being capsules, endoscopy, or nasal
tubes. Fresh stool was prepared for 95% of patients and 75% of donors were relatives.
Resolution of C. difficile was achieved in 87.7% (206/234) after one fecal
transplantation, and 93% required two or greater treatments. Colonoscopy was 84% effective,
while combining upper endoscopy, capsule, and nasal tube was 92% effective (P=0.202). FMT
was more effective if one condition caused immune suppression instead of 2 or more (93% vs
78%) causes (OR 0.24; 95% CI, 0.11-0.51, p<0.0001).
For safety, all 303 were able to be included in the data. Two deaths were reported in
patients with solid organ transplant due to complications from pneumonia and aspiration
pneumonitis during sedation. Moderate to severe adverse events reported included
hospitalization (10), unspecified life-threatening complications (7), inflammatory bowel disease
flare (7), bacteremia or infection (5), and colectomy (2). Abdominal pain, diarrhea, nausea, fever,
and diverticulitis are considered minor complications that 28 patients reported.
Tavoukjian (2019) compiled data into a review of FMT for the decolonization of
antibiotic resistant bacteria. The three most significant studies included: Bilinski 67% (12/18),
Dinh 53% (9/17), and Singh 20% (3/15) achieved success at one month. Combined, they were
able to decolonize the gut in 46% of cases (24/50; 95% CI, 0.20-0.74). Bilinksi noted at six
months that 22% (four) had recolonization of resistant bacteria.
Pseudomonas aeruginosa was the easiest bacteria to eradicate with four cases reaching
complete decolonization. Klebsiella pneumoniae was the least responsive to treatment with New
Delhi metallo-betalactamase (4/11; 36%), ESBL (2/5; 40%), and oxa-cillinase (3/6; 50%). E. coli
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has ESBL (15/26; 57%) and OXA-48 (2/3; 66%) strains that were eliminated in over half of
those colonized. Vancomycin-resistant Enterococci was tested for vanA (5/8; 62%) and VanB
(1/2; 50%) genes. Stenotrophomonas maltophilia and Acinetobacter ursingii each had one person
tested and lacked colonization after FMT.
Unfortunately, this study demonstrated low-quality evidence with a high risk of bias
(heterogeneity high; P=0.0244). In lieu of one fatality this summer due to MDRO, further studies
(RCT) on the efficacy of FMT for drug resistant bacteria may provide a benefit beyond treatment
with C. difficile. Limiting factors include the small sample size, a single author reviewing the
literature, single trials without direct comparison, and that all studies were performed in Europe.
Youngster et al. (2016) sought to establish the effectiveness of oral frozen FMT capsules
in the treatment of recurrent or refractory CDI. By using oral capsules, the risks involved with
endoscopy or colonoscopy are negated, as well as procedural discomfort. Age varied from 7-95
years-old. Absolute exclusion criteria involved neutropenia or prednisone dose over 40 mg/day;
other immunosuppressants were considered on an individual basis by the referring provider.
Fecal material was collected, blended, and suspended with sterile saline and 10% glycerol
in Hypromellose capsules. Storage was at -80 degrees Celsius prior to use. Antibiotic treatment
for CDI was stopped 24-48 hours prior to FMT treatment, which consisted of 15 capsules on two
consecutive days. The total therapy involved about 48 grams of fecal material. If C. difficile
tested positive, the patients were given another course of antibiotics with the choice of FMT.
Follow-up was done via telephone in weeks one and two, and at months two and six. A
standardized questionnaire accompanied the phone call.
The primary endpoint of the study was considered with the resolution of infection at eight
weeks, of which 82% (147/180) were successful. After a second FMT, another 17 were cured,
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bringing the results up to 91 percent. Seven patients either denied, or were unresponsive to
another treatment with FMT, and were given long-term oral vancomycin. Relapse occurred in
five individuals spontaneously, as well as due to antibiotic or chemotherapy treatment.
Adverse effects noted in the study ranged from mild to severe. One patient had fever
greater than 39 degrees Celsius, two were diagnosed with ulcerative colitis, and six were
hospitalized due to relapsing CDI or diarrhea. Diarrhea was the most common adverse event
reported in greater than half the populous (112). Other mild or moderate events included fatigue
(54), nausea or bloating (45), abdominal pain (40), dizziness, UTI, or URI (12), vomiting (5),
and fever (3). Serious events that were unrelated to treatment included 26 hospitalizations and 14
deaths.
For initial CDI, the research demonstrates vancomycin or fidaxomicin to be superior to
metronidazole. While the guidelines to donor selection and screening stool are still being
constructed, they should be more defined as more is learned about the risks and benefits of FMT.
There are many different methods to administer FMT therapy, but the adverse outcomes remain
similar. Most adverse side effects are minimal and self-limited, with increased risk for those over
65 years of age, residing in a long-term care facility, immunocompromised, taking PPIs or
antibiotics, and prolonged hospital stays. Death has occurred from MDRO, or complications to
the procedure, so caution must be used with treatment. After multiple failed attempts with
antibiotics, it is important to consider FMT, and discuss the risks and benefits with the patient.
Discussion
Clostridioides difficile infection is common within the community and hospital. Risk
factors include age greater than 65 years old, antibiotic use, long-term care facilities, hospital
stay, and gastric acid suppressants. With antibiotic stewardship, some geographical areas could
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see a decrease of infection by as much as 23 percent (Zacharioudakis et al., 2019). For
community-acquired disease, Khan et al. (2014) demonstrated a primary cure rate of 100 percent,
while the hospital-acquired group was 82 percent. When considering recurrence of disease,
community-acquired was more common than hospital acquired at 34.4% versus 21.8%,
respectfully (Aldrich et al., 2019). Hospital-acquired infection was more common amongst
recent antibiotic use (61%; P=0.004), and immunosuppression (60%; P<0.001).
When should FMT be considered in therapy?
Initial C. difficile infection can be properly managed with oral antibiotics. If recurrent
infection occurs and is unable to be managed with antibiotics alone, FMT has demonstrated
efficacy and safety. No standard amount of recurrences are required before trying FMT after
failed antibiotic therapy; it is to be discussed and decided between the patient and provider.
Locally, three or four attempts are made with antibiotics prior to FMT. Upon persistent
recurrence, the normal microbial flora may need to be reset and FMT should be considered.
Is oral FMT more effective than rectal FMT in the treatment of recurrent CDI?
Agrawal et al. (2016) looked at the safety profile in the high-risk population of those 6597 years-old because 92% of deaths related to CDI are in the elderly. The study was mostly
(80%) performed via colonoscopy for severe, complicated, or recurrent CDI. The overall cure
rate was 83% on the first installation, and is consistent with a study by Aldrich et al. (2019)
where 80% had an initial cure with FMT and 70% of those patients were completed via
colonoscopy.
Hagel et al. (2016) conducted a retrospective study that used colonoscopy in 41% of
patients and upper GI route in 57% with a primary response in 84% by 30 days. Colonoscopy
had 89 percent cure by 30 days, versus capsule at 84 percent, and duodenal at 79 percent. The
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study performed by Hvas et al. (2019), did not have results for differentiating gastrointestinal
versus rectal administration, as it was comparing FMT to oral antibiotics. Colonoscopy was
performed in 79% and primary resolution was achieved in 71% with FMT.
In comparing oral administration (23%) versus retention enema (35%), and colonoscopy
(42%), Rao et al. (2016) found 89% had primary resolution after FMT. Unfortunately, the study
did not delineate how each mode of administration fared in respect to the resolution. In a
systematic review of 44 studies (Shogbesan et al., 2018) primary resolution was achieved in 84%
of colonoscopy procedures, while combining upper endoscopy, capsule, and nasal tube was 92%
effective (P=0.202).
Limitations to direct comparison include the possibility for more studies than what is
included here, as well as trying to correlate different studies with different methods. From the
studies reviewed, it would appear that colonoscopy and upper GI route of administration are
within 10% effectiveness. Whether oral or fecal administration, FMT will eradicate disease on
the first procedure for most. Oral administration will reduce the risks involved with anesthesia,
or using a colonoscope. In some studies, the number of patients trended higher for colonoscopy
due to their facility protocol, patient preference, or other unknown reason.
What are the current guidelines and screening for stool donors?
Guidelines have not been standardized for the screening of stool donors. Some facilities
use donor companies, while others use relatives or close friends. Some institutions might use
similar screening precautions; however, there is still missing information in regards to FMT,
making it challenging to regulate. At the University of Toledo Medical Center (Khan et al.,
2014) stool testing consisted of CDI toxin PCR, bacterial culture for enteric pathogens, ova and
parasites, cryptosporidium antigen and microspora. Serum testing included Hepatitis A, B, C,
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antibodies for HIV 1 and 2, human T lymphotropic virus, and Helicobacter pylori. Vyas et al.
(2015) performed similar testing with the addition of a comprehensive medical history that
included recent travel to areas with endemic diarrhea, high-risk sexual activity, infectious and
autoimmune disease, cancer, and inflammatory bowel disease.
In addition to the other two contributions, Woodworth et al. (2017) highlighted the
importance of screening for potential pathogens via PCR; however, this has yet to be validated.
The risk with asymptomatic carriers of C. difficile, BMI greater than 30, and multidrug resistant
organisms could be utilized as exclusion criteria to donation. Current research into conditions
that may impact the normal microbiome adversely will help screening guidelines as more is
discovered.
Considering the recent death due to MDRO, it is crucial to include this into current
screening guidelines via questionnaire and testing. Proper screening should include all of the
above concerns, albeit thorough, it is necessary because FMT is still in its infancy and all of the
risks involved are still unknown. Utilizing a donor stool bank will provide increased consistency
with screening protocols and access to the product.
Does the adverse side effect of therapy differ based on administration route?
In the studies by Agrawal et al. (2016), Hagel et al. (2016) and Hvas et al. (2019), the
majority of treatments were by colonoscopy. Less than 5% of patients complained of diarrhea,
constipation, nausea, fever, abdominal pain, or irritable bowel syndrome. Serious adverse events
related to FMT consisted of six hospital admits due to diarrhea. Fourteen deaths occurred but
were declared unrelated to FMT treatment.
Lee et al. (2016) used retention enema for every patient, while Youngster et al. (2016)
utilized oral capsules in their study. Despite different routes of administration, both demonstrated
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diarrhea, flatulence, constipation and abdominal cramps amongst the most commonly reported
adverse events. Hospitalization and death unrelated to treatment occurred in both; however, four
died from unresolved CDI in the enema group.
Comprehensive systematic reviews were performed by Rao et al. (2016) and Shogbesan
et al. (2018). The majority of side effects seen were mild and self-limited, which is consistent
with other studies reviewed. Severe adverse events reported included hospitalization, lifethreatening complications, inflammatory bowel disease flare, infection, and colectomy. Deaths
were unrelated to FMT.
Aside from the single studies with one mode of administration, the route of
administration was not delineated, which makes correlation with adverse side effects imperfect.
Many of the studies reviewed had similar adverse effects despite various modes of
administration. Except in one recent report, deaths were not related to FMT itself. At this time, it
is undetermined if the route of administration would affect the adverse reaction demonstrated;
however, theoretically it is plausible. Dedicated studies would need to be performed to correlate
this specifically.
Application to Clinical Practice
Many of those in practice will eventually take care of a patient with C. difficile infection.
It may be on their initial encounter, or after multiple failed attempts to restore the normal
microbiome. Oral antibiotics are the mainstay for treatment in initial disease due to minimal
adverse side effects, and low cost. Early in recurrent disease it is beneficial to use an antibiotic
that was not part of the initial treatment, or try pulsed regimens. After multiple treatment failures,
it is time to consider FMT and discuss options with an infectious disease provider.
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The guidelines for FMT continue to evolve as we learn more, however, they currently are
going to be different depending on region. It helps to understand the facility protocol with
respect to donor stool; is it provided from a company such as OpenBiome, or is the patient
required to bring in a blender and close friend or family member? It is beneficial to be aware of
the screening tests required for donor stool, as well. With knowledge of local protocols, it may
make it easier to discuss with your patient about their desired therapy. FMT in our region is not
typically utilized prior to three or four treatments with oral antibiotics, because all the risks of
FMT are still not identified.
Typically, adverse events seen are mild and self-limiting, lasting for a few days to a
week. Oral antibiotics won’t change the gut microbiome, but FMT has demonstrated the ability
to “reset” the normal flora to pre-C. difficile status. While deaths have occurred from FMT, it is
still considered to be quite safe with proper screening of donor stool, a lack of comorbidities, and
age less than 65 years-old.
Recurrent CDI is becoming more common and it is vital to prepare the patient with risks,
benefits, and alternatives to treatment prior to infectious disease referral. This confers patients to
make an informed decision regarding their own care. As discussed, FMT may have bias related
to both prescriber and patient. To alleviate bias providers should understand their local protocol
involving recurrent CDI. Patients are more apt to try FMT if they understand the procedure, the
safety, and the efficacy of treatment.

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

37

References
Agrawal, M., Aroniadis, O., Brandt, L., Kelly, C., Freeman, S., Surawicz, C., … & Smith, R.
(2016). The long-term efficacy and safety of fecal microbiota transplant for recurrent,
severe, and complicated clostridium difficile infection in 146 elderly individuals. Journal
of Clinical Gastroenterology, 50, (5), 403-407.
http://dx.doi.org/10.1097/MCG.0000000000000410
Aldrich, A., Argo, T., Koehler, T., & Olivero, R. (2019). Analysis of treatment outcomes for
recurrent clostridium difficile infections and fecal microbiota transplantation in a
pediatric hospital. The Pediatric Infectious Disease Journal, 38(1), 32-36.
https://doi.org/10.1097/INF.0000000000002053
Allegretti, J., Mullish, B., Kelly, C., & Fischer, M. (2019). The evolution of the use of faecal
microbiota transplantation and emerging therapeutic indications. The Lancet, 394
(10196), 420-431. https://doi.org/doi: 10.1016/S0140-6736(19)31266-8
Clarkin, C., Quist, S., Shamis, R., King, A., & Shah, B. (2019). Management of clostridioides
difficile infection. Critical Care Nurse, 39(5), e1-e12.
http://dx.doi.org/10.4037/ccn2019841
Guery, B., Galperine, T., & Babur, F. (2019). Clostridioides difficile: Diagnosis and treatment.
BMJ, 366, (14609), 1-14. https://doi.org/10.1136/bmj.l4609
Hagel, S., Fischer, A., Ehlermann, P., Frank, T., Sturm, A., Link., A. … Stallmach, A., &
Vehreschild, M. (2016). Fecal microbiota transplant in patients with recurrent clostridium
difficile infection. Deutsches Arzteblatt International, 113, 583-589.
https://doi.org/10.3238/arztebl.2016.0583

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

38

Hvas, C., Dahl Jorgensen, S., Jorgensen, S., Storgaard, M., Lemming, L., Hansen, M., … &
Dahlerup, J. (2019). Fecal microbiota transplantation is superior to fidaxomicin for
treatment of recurrent clostridium difficile infection. Gastroenterology, 156, (5), 13241332. https://doi.org/10.1053/j.gastro.2018.12.019
Important safety alert regarding use of fecal microbiota for transplantation and risk of serious
adverse reactions due to transmission of multi-drug resistant organisms. (2019).
Retrieved from https://www.fda.gov/vaccines-blood-biologics/safety-availabilitybiologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-riskserious-adverse
Khan, M., Sofi, A., Ahmad, U., Alaradi, O., Khan, A., Hammad, T., … & Nawras, A. (2014).
Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal
microbiota transplantation in relapsing and refractory community-and hospital-acquired
Clostridium difficile infection. Canadian Journal of Gastroenterology & Hepatology,
28(8), 434–438. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210234/
Lee, C., Steiner, T., Petrof, E., Smieja, M., Roscoe, D., Nematallah, A., … & Kim, P. (2016).
Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in
patients with recurrent clostridium difficile infection. JAMA, 315(2), 142-149.
http://dx.doi.org/10.1001/jama.2015.18098
Nearly half a million Americans suffered from Clostridium difficile infections in a single year.
(n.d.). Retrieved from https://www.cdc.gov/media/releases/2015/p0225-clostridiumdifficile.html

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

39

Rao, K., & Safdar, N. (2016). Fecal microbiota transplantation for the treatment of clostridium
difficile infection. Journal of Hospital Medicine, 11(1), 56-61.
https://doi.org/10.1002/jhm.2449
Shogbesan, O., Poudel, D., Victor, S., Jehangir, A., Fadahunsi, O., Shogbesan, G., & Donato, A.
(2018). A Systematic review of the efficacy and safety of fecal microbiota transplant for
clostridium difficile infection in immunocompromised patients. Canadian Journal of
Gastroenterology & Hepatology, 2018, (1394379), 1-10.
https://doi.org/10.1155/2018/1394379
Song, J., & Kim, Y. (2019). Recurrent Clostridium difficile Infection: Risk Factors, Treatment,
and Prevention. Gut and Liver, 13(1), 16–24.
http://dx.doi.org/10.4037/ccn201984110.5009/gnl18071
Tavoukjian, V. (2019). Faecal microbiota transplantation for the decolonization of antibioticresistant bacteria in the gut: A systematic review and meta-analysis. Journal of Hospital
Infection, 102, (2), 174-188. https://doi.org/10.1016/j.jhin.2019.03.010
Vyas, D., Aekka, A., & Vyas, A. (2015). Fecal transplant policy and legislation. World Journal
of Gastroenterology, 21(1), 6–11. https://dx.doi.org/10.3748/wjg.v21.i1.6
Woodworth, M., Carpentieri, C., Sitchenko, K., & Kraft, C. (2017). Challenges in fecal donor
selection and screening for fecal microbiota transplantation: A review. Gut Microbes,
8(3), 225–237. https://dx.doi.org/10.1080/19490976.2017.1286006
Youngster, I., Mahabamunuge, J., Systrom, H., Sauk, J., Khalili, H., Levin, J., … & Hohmann,
E. (2016). Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent
Clostridium difficile infection. BMC Medicine, 14 (134), 1-4.
https://doi.org/10.1186/s12916-016-0680-9

TREATMENT OF CLOSTRIDIOIDES DIFFICILE

40

Zacharioudakis, I., Zervou, F., Shehadeh, F., Mylona, E., & Mylonakis, E. (2019). Association of
community factors with hospital-onset clostridioides (clostridium) difficile infection: A
population based U.S.-wide study. EClinicalMedicine, 8, 12–19.
https://doi.org/10.1016/j.eclinm.2019.02.001

